Who is sponsoring NCT03005002?

NCT03005002 is sponsored by City of Hope Medical Center.

What drugs are being tested in NCT03005002?

Interventions in NCT03005002: Durvalumab, Laboratory Biomarker Analysis, Tremelimumab.

What condition does NCT03005002 study?

NCT03005002 studies Metastatic Carcinoma in the Liver, MLH1 Gene Mutation, MSH6 Gene Mutation, PMS2 Gene Mutation, Stage IV Colorectal Cancer, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer.

Is NCT03005002 still recruiting?

NCT03005002 is currently completed. Last updated 26 December 2019.

Last reviewed 2019-12-26 · How we verify

NCT03005002

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the Liver

Completed Phase 1 Last updated 26 December 2019

What this trial tests

Phase 1 trial testing Durvalumab in Metastatic Carcinoma in the Liver in 9 participants. Completed in 26 November 2019.

Timeline

28 June 2017

Primary endpoint
26 November 2019

26 November 2019

Quick facts

Lead sponsor	City of Hope Medical Center
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	9
Start date	28 June 2017
Primary completion	26 November 2019
Estimated completion	26 November 2019
Sites	1 location across United States

Drugs / interventions tested

Durvalumab — full drug profile →
Laboratory Biomarker Analysis — full drug profile →
Tremelimumab (TREMELIMUMAB) — full drug profile →

Conditions studied

Metastatic Carcinoma in the Liver — all drugs for Metastatic Carcinoma in the Liver →
MLH1 Gene Mutation — all drugs for MLH1 Gene Mutation →
MSH6 Gene Mutation — all drugs for MSH6 Gene Mutation →
PMS2 Gene Mutation — all drugs for PMS2 Gene Mutation →

Sponsor

City of Hope Medical Center

Who can join

19 and older, any sex, with Metastatic Carcinoma in the Liver or MLH1 Gene Mutation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This pilot clinical trial studies the side effects and how well durvalumab and tremelimumab work in treating patients with microsatellite stable colorectal cancer that has spread to the liver. Monoclonal antibodies, such as durvalumab and tremelimumab, may interfere with the ability of tumor cells to grow and spread.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

PD-1 and PD-L1 inhibitors in cold colorectal cancer: challenges and strategies.
Lin KX, Istl AC, Quan D, Skaro A, et al · · 2023 · cited 90× · PMID 37831146 · DOI 10.1007/s00262-023-03520-5
Is There a Place for Immunotherapy for Metastatic Microsatellite Stable Colorectal Cancer?
Ghiringhelli F, Fumet JD. · · 2019 · cited 61× · PMID 31447840 · DOI 10.3389/fimmu.2019.01816
Safety of selective internal radiation therapy (SIRT) with yttrium-90 microspheres combined with systemic anticancer agents: expert consensus.
Kennedy A, Brown DB, Feilchenfeldt J, Marshall J, et al · · 2017 · cited 32× · PMID 29299370 · DOI 10.21037/jgo.2017.09.10
A Pilot Feasibility Study of Yttrium-90 Liver Radioembolization Followed by Durvalumab and Tremelimumab in Patients with Microsatellite Stable Colorectal Cancer Liver Metastases.
Wang C, Park J, Ouyang C, Longmate JA, et al · · 2020 · cited 30× · PMID 31857446 · DOI 10.1634/theoncologist.2019-0924
The Emerging Role of Checkpoint Inhibition in Microsatellite Stable Colorectal Cancer.
Hermel DJ, Sigal D. · · 2019 · cited 26× · PMID 30654522 · DOI 10.3390/jpm9010005
Combination therapy with PD-1/PD-L1 blockade: An overview of ongoing clinical trials.
Johnson CB, Win SY. · · 2018 · cited 26× · PMID 29632719 · DOI 10.1080/2162402x.2017.1408744
Landscape of Immunotherapy Options for Colorectal Cancer: Current Knowledge and Future Perspectives beyond Immune Checkpoint Blockade.
Gorzo A, Galos D, Volovat SR, Lungulescu CV, et al · · 2022 · cited 21× · PMID 35207516 · DOI 10.3390/life12020229
Perspectives of Targeting Autophagy as an Adjuvant to Anti-PD-1/PD-L1 Therapy for Colorectal Cancer Treatment.
ALKhemeiri N, Eljack S, Saber-Ayad MM. · · 2025 · cited 5× · PMID 40422248 · DOI 10.3390/cells14100745

Verify or expand the search:

Other trials of Durvalumab

Trials testing the same drug.

NCT07507968 — TNT With FLOT/Durvalumab Plus Post-OP Durvalumab for Resectable Gastroesophageal Adenocarcinoma · Phase 2 · not yet recruiting
NCT07332351 — Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle · Phase 2 · not yet recruiting
NCT07339059 — Phase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Ce · Phase 2 · recruiting
NCT07531095 — Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) · Phase 1 · not yet recruiting
NCT07459634 — A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC · Phase 2 · not yet recruiting

Other recruiting trials for Metastatic Carcinoma in the Liver

Currently open trials in the same condition.

NCT06860815 — Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Br · Phase 2 · recruiting

Other City of Hope Medical Center trials

Trials by the same sponsor.

NCT07365306 — Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant · Phase 2 · not yet recruiting
NCT07218692 — RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy · Phase 2 · not yet recruiting
NCT07363408 — Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment · Phase 1 · not yet recruiting
NCT07226102 — Virtual Mental Health Intervention to Address Fear of Progression for Women With High Risk or Stage III-IV Gynecologic o · NA · withdrawn
NCT07225855 — Geriatric Assessment and Management for Older Adults Undergoing Chemotherapy and Radiation Therapy for Head and Neck Can · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03005002 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by City of Hope Medical Center
Last refreshed: 26 December 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03005002.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing